<bill session="117" type="s" number="4535" updated="2022-12-29T18:33:45Z">
  <state datetime="2022-07-14">REFERRED</state>
  <status>
    <introduced datetime="2022-07-14"/>
  </status>
  <introduced datetime="2022-07-14"/>
  <titles>
    <title type="display">FDASRA Act of 2022</title>
    <title type="short" as="introduced">FDASRA Act of 2022</title>
    <title type="short" as="introduced">Food and Drug Administration Simple Reauthorization Act of 2022</title>
    <title type="short" as="introduced" partial="1">Biosimilar User Fee Amendments of 2022</title>
    <title type="short" as="introduced" partial="1">Generic Drug User Fee Amendments of 2022</title>
    <title type="short" as="introduced" partial="1">Medical Device User Fee Amendments of 2022</title>
    <title type="short" as="introduced" partial="1">Prescription Drug User Fee Amendments of 2022</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="B001135"/>
  <cosponsors/>
  <actions>
    <action datetime="2022-07-14">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2022-07-14" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="h" number="7667" relation="unknown"/>
    <bill session="117" type="s" number="4348" relation="unknown"/>
    <bill session="117" type="h" number="6833" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-11-21T16:12:49Z" status="Introduced in Senate">Food and Drug Administration Simple Reauthorization Act of 2022 or the FDASRA Act of 2022

This bill reauthorizes the authority of the Food and Drug Administration to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts.</summary>
</bill>
